Bilateral Spontaneous Supraspinatus Tendon Rupture Under Prolonged BRAF/MEK Targeting Treatment in a Melanoma Patient.
braf mutation
braf/mek targeting
melanoma
rotator cuff tear
side effects
tendon rupture
trametinib
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
accepted:
14
12
2023
medline:
15
1
2024
pubmed:
15
1
2024
entrez:
15
1
2024
Statut:
epublish
Résumé
The B-Raf proto-oncogene, serine/threonine kinase (BRAF)/ mitogen-activated protein kinase kinase (MEK) targeting agents have become the treatment of choice for BRAF-mutated melanoma during the last decade. However, it is possible that some long-term adverse events of these drugs have not yet been reported. A case of bilateral spontaneous, non-traumatic, supraspinatus tendon rupture in a 65-year-old Caucasian male suffering metastatic melanoma under prolonged and successful combination treatment with dabrafenib plus trametinib is presented. These damages could not be attributed to some other probable cause. The ruptured tendons were promptly restored arthroscopically. Oncologists should remain vigilant for the early detection of potential side effects of BRAF/MEK targeting agents that have not been systematically recorded yet but may appear and affect patients in the long run.
Identifiants
pubmed: 38222175
doi: 10.7759/cureus.50567
pmc: PMC10788042
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e50567Informations de copyright
Copyright © 2023, Bafaloukos et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.